Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07045701 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FMXIN002 in Patients at Risk of Anaphylaxis

StatusEnrolling by Invitation
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 1, 2025 (before its estimated June 12, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis. Study Design • Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more rapidly-than IM epinephrine, as measured by clinical parameters.
Trial Details
NCT Number NCT07045701
Lead Sponsor Nasus Pharma
Conditions
(from sponsor)		 Anaphylaxis Food
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov